Everest Medicines ("Everest" poʻo le "Kamupani"), o se kamupani biopharmaceutical o loʻo taulaʻi i le atinaʻeina ma le faʻatauina o oloa faʻafomaʻi faʻafomaʻi e faʻafeiloaʻi ai manaʻoga faʻapitoa faʻafomaʻi mo tagata mamaʻi i Asia, na faʻasalalau i aso nei ua toe faʻatau mai le 1,095,000 sea masani e tusa ma le HK$50 miliona. i le maketi tatala i le vaitaimi mai Oketopa 4, 2021 ia Oketopa 29, 2021, i se tau averesi o HK$45.63 i le sea. O lo'o maua fa'amatalaga tau fefa'ataua'iga ta'ito'atasi i le vaega o teufaafaigaluega tupe o le upegatafa'ilagi a le Kamupani.
O toe fa'atau na faia i lalo o le HK$100 miliona sea toe fa'atauina polokalame fa'alauiloa ma amata mai ia Aokuso 30, 2021. I le tau o sea o lo'o iai nei, e talitonu le Kamupani o lo'o fefa'ataua'i ana sea i se fa'aitiitiga tele i lo latou tau fa'avae, ma e ono fa'aauau pea ona toe fa'atau mai sea i totonu. maketi tatala. O lo'o fa'amaoni atoatoa le Kamupani i le fa'atupuina o le tau mo tagata e umia sea ma e malosi lona talitonuga i lana va'aiga i le lumana'i. E oʻo mai ia Iuni 30, 2021, sa maua e le Kamupani le RMB3,971.0 miliona tinoitupe ma tinoitupe tutusa.
O le a faia e le Kamupani soʻo se faʻatauga o sea e tusa ai ma le faʻamaumauga ma mataupu o faʻasalalauga a le Kamupani, Tulafono e Pulea ai le Lisi o Faʻamalumaluga i luga o le Stock Exchange a Hong Kong Limited, Codes on Takeovers and Mergers and Share Buybacks, the Companies Law of le Cayman Islands ma tulafono talafeagai uma ma tulafono faatonutonu e noatia i ai le Kamupani.
OA MEA E AVEA MAI LENEI TUSI:
- O le a faia e le Kamupani soʻo se faʻatauga o sea e tusa ai ma le faʻamaumauga ma mataupu o faʻasalalauga a le Kamupani, Tulafono e Pulea ai le Lisi o Faʻamalumaluga i luga o le Stock Exchange a Hong Kong Limited, Codes on Takeovers and Mergers and Share Buybacks, the Companies Law of le Cayman Islands ma tulafono talafeagai uma ma tulafono faatonutonu e noatia i ai le Kamupani.
- Or the “Company”), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Asia, today announced that it has repurchased 1,095,000 ordinary shares equivalent to approximately HK$50 million in the open market in the period from October 4, 2021 to October 29, 2021, at an average price of HK$45.
- At current share price, the Company believes its shares are trading at a substantial discount to their underlying value, and may continue to repurchase shares in open market.
